NCT02984995 - Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 8, 2016

Primary Completion Date

March 28, 2018

Study Completion Date

September 14, 2018

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG

Quizartinib

Quizartinib was orally administered once daily every morning. Treatment with quizartinib was administered in 28-day cycles and continued until the discontinuation criteria for treatment were met.

Trial Locations (27)

Unknown

Aichi

Akita

Chiba

Fukui

Fukuoka

Fukushima

Gifu

Gunma

Hiroshima

Hokkaido

Ibaraki

Kagoshima

Kanagawa

Kyoto

Miyagi

Nagasaki

Nara

Okayama

Osaka

Saga

Saitama

Shizuoka

Tochigi

Tokyo

Toyama

Yamagata

Yamanashi